Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
AstraZeneca (AZN) Stock Price & Analysis
5,839 Followers
AZN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$59.57 - $74.94
Previous Close$68.53
Volume2.13M
Average Volume (3M)6.32M
Market Cap
$209.23B
Enterprise Value$232.55B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)35.7
Beta0.52
Next Earnings
Apr 25, 2024EPS Estimate
$0.97Last Dividend Ex-Date
Feb 22, 2024Dividend Yield2.08%
Share Statistics
EPS (TTM)1.92
Shares Outstanding3,100,378,676
10 Day Avg. Volume6,013,292
30 Day Avg. Volume6,319,070
Standard Deviation0.06
R-Squared0.21
Alpha0.00648
Financial Highlights & Ratios
Price to Book (P/B)-11.37
Price to Sales (P/S)9.00
Price to Cash Flow (P/CF)19.70
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.24
Enterprise Value/Gross Profit6.19
Enterprise Value/Ebitda25.60
Forecast
1Y Price Target
$80.56Price Target Upside17.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
AstraZeneca News
PremiumStock Analysis & Ideas
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
Bulls Say, Bears Say
Bulls Say
Drug ApprovalEnhertu has been granted the first antibody-drug conjugate tumor agnostic approval by the FDA, highlighting a groundbreaking advance in cancer treatment and broadening its market potential.
Financial GrowthProjected revenues from newly approved indications for products like Enhertu suggest a significant uptick, marking a strong contribution to the overall financial growth of the company.
Strategic AcquisitionThe acquisition of Fusion Pharmaceuticals is set to enhance the company's late-stage pipeline and expand its footprint in the radioligand therapy space, a cutting-edge approach in cancer treatment.
Bears Say
Clinical Trial OutcomeTrodelvy failed to achieve the primary endpoint of overall survival (OS) benefit vs docetaxel in the Phase 3 EVOKE-01 study.
Drug ApprovalThe FDA did not grant approval for HER2 expression levels less than IHC3+, limiting the drug's use to a subset of patients.
Financial CommitmentThere is an $800 million upfront payment and potential additional regulatory milestones that could amount to $250 million, representing a significant financial commitment.
---
Ownership Overview
0.00%
Insiders
6.83% Mutual Funds
0.86% Other Institutional Investors
92.31% Public Companies and Individual Investors
AZN FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was $59.57 and its highest was $74.94 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Currently, no data Available
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Apr 25, 2024 which is in 5 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Feb 08, 2024. The company reported $0.725 earnings per share for the quarter, missing the consensus estimate of $0.731 by -$0.006.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of $0.96 which represents an annual dividend yield of 2.08%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is $0.97.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,100,378,700 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of $0.725 in its last earnings report, missing expectations of $0.731. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Among the largest hedge funds holding Astrazeneca Plc’s share is PRIMECAP Management Co. It holds Astrazeneca Plc’s shares valued at 3B.
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.56 (17.85% Upside)
$80.56 (17.85% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.91%
12-Months-Change
Fundamentals
Return on Equity
15.63%
Trailing 12-Months
Asset Growth
4.80%
Trailing 12-Months
Company Description
Astrazeneca Plc
Founded in 1992, UK-based AstraZeneca Plc is a leading global pharmaceutical company, which is engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases.
---
AZN Company Deck
---
AZN Earnings Call
Q4 2024
0:00 / 0:00
---
AZN Stock 12 Months Forecast
Average Price Target
$80.56
▲(17.85% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+15.30%
assigned a buy rating last month
Copying Steve Scala's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.30% per trade.
---